Um alle Therapiemöglichkeiten zum Wohle und zur Gesundheit unserer Patienten auszuschöpfen beteiligt sich das Hautkrebszentrum in großem Umfang an klinischen Studien. Eine Übersicht über alle laufenden onkologischen Studien am Universitätsklinikum Erlangen bietet die Studiendatenbank des Comprehensive Cancer Centers Erlangen-EMN .
Bei Fragen zu aktuell laufenden onkologischen Studien an der Hautklinik des Uniklinikums Erlangen stehen wir Ihnen gerne zur Verfügung. Bitte melden Sie sich telefonisch unter 09131/85-45902 (Frau Parnitzke), -45861 (Frau Simanek) oder per Mail unter onkstudienzentrale.DE@uk-erlangen.de. Wir setzten uns dann umgehend mit Ihnen in Verbindung.
Aktuelle Studien
Kurztitel | Indikation | Studien-Titel | Phase | Eudra-CT: |
Oncobiome | Melanoma, breast-, colon- or lung-cancer | Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. | 2 | 2007-007847-28 |
Promit PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy | Unresectable or metastatic melanoma | A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy rechallenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade | 2 | 2017-003556-23 |
Adoreg Register | MM, MCC, SCC, BCC | gem. §3 Nr. 1 der Veinbarung zur Dokumentation und Übermittlung von Behandlungsverläufen in ein prospektives Online-Register zur Versorgungsforschung in der dermatologischen Onkologie (ADOREG)) | NIS | XXX |
MCC-Trim | Merkel cell carcinoma | Noninterventional cohort registry study to assess characteristics and management of patients with merkel cell carcinoma in Germany | NIS | EU PAS register number EUPAS25338 |
Field-Cancerization | PEK der Haut mit Feldkanzerisierung | Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced field cancerization – An open label, prospective, observational biomarker study of the DeCOG | NIS | 2021-006372-17 |
Combi-EU | melanoma (adjuvant setting) | BRAF-/MEK-Inhibition with Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: a non-interventional observatory Study | NIS | EUMR-18001 |
CemiSkin | advanced CSCC | Two cohort registry study for patients with advanced CSCC treated with Cemiplimab or other approaches | NIS | OBS16381 |
InflaRx | SCC | OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) | 2 | 2020-000864-42 |
BMS CA244-098 | Melanom | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab-Nivolumab Fixed-dose Combination (BMS-986213) versus Nivolumab after Complete Resection of Stage III-IV Melanoma | 3 | 2021-001641-13 |
Kartos | MCC | A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve | 1b/2 | 2020-002820-35 |
IMA401-101 | Melanom | A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients with Recurrent and/or Refractory Solid Tumors | 1a/1b | 2021-004326-30 |
Pfizer STARBOARD C4221016 | Melanom | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | 3 | 2020-004850-31 |
BLUE-263-1201 | Mastocytosis | A Randomized, Double-Blind, Placebo- Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2/3 | 2020-005173-28 |
Biotech IO102-IO103-013 | Melanom | An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma | 3 | 2021-004594-32 |